Skip to content

A prospective, randomized, half-face self-controlled clinical trial of an optimized protocol for intense pulsed light (IPL-RRB- treatment of facial photoaging

A prospective, randomized, half-face self-controlled clinical trial of an optimized protocol for intense pulsed light (IPL-RRB- treatment of facial photoaging

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500112082
Enrollment
Unknown
Registered
2025-11-10
Start date
2025-12-01
Completion date
Unknown
Last updated
2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Photoaging of facial skin

Interventions

Control side:Single-wavelength filter IPL therapy
Test side:Multi-wavelength filter IPL therapy

Sponsors

Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1.Healthy subjects aged 18-75 years (including upper and lower limits) with mild to moderate light impairment on the face; 2 with a clear clinical diagnosis, consent treatment and observation period without any other than the test treatment of facial dermatosis surgery or treatment; 3 right and left facial photoaging no significant asymmetry; 4.After fully understanding the treatment plan and the risk, they are willing to sign the informed consent form, accept the self-controlled trial, and cooperate with the follow-up.

Exclusion criteria

Exclusion criteria: 1.Pregnant or lactating women; 2 patients with a history of facial active dermatosis, poor wound healing, and keloid formation; 3.Patients currently participating in other clinical trials 4.Subjects who had received laser, chemical exfoliation, or tamponade in the previous 6 months; 5.patients with a history of photosensitivity, who were taking photosensitivity medication, or who had a baseline tan.

Design outcomes

Primary

MeasureTime frame
logo Light aging scale;

Secondary

MeasureTime frame
Safety Assessment;VISIA;

Countries

China

Contacts

Public ContactLin Xiaoxi

Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine

linxiaoxi@126.com+86 137 0199 7136

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026